NUCB2 and breast carcinoma: In prostate cancer [22, 23], gastric cancer [24], colon cancer [25], breast carcinoma [19, 20], and endometrial carcinoma [26], high expression of NUCB2 was linked to poor prognosis due to the enhancement in cell proliferation and migration.